Q1 2026 Management View "We've had a very strong start to the year" and "the growth products are now generating $850 million in the first quarter, and that's up 12%" (President, CEO & Director ...
Biogen’s growth was expected to stay flat through the 2030s. A key acquisition and busy late-stage pipeline have relieved the ...
Biogen (NASDAQ:BIIB) executives pointed to a “very strong start” to 2026, highlighting growth in key products, progress ...
Biogen will buy Apellis Pharmaceuticals for about $5.6 billion, adding a promising kidney disease drug to broaden its ...
Biogen is spending $5.6 billion to buy Apellis Pharmaceuticals in a deal that aligns with its own strategy to bring to market a new treatment for people undergoing kidney transplants and suffering ...
Biogen (BIIB) stock is in focus as the company beats forecasts with its Q1 2026 financials and trims its full-year earnings ...
Pharmaceutical Technology on MSN
Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout
This acquisition will add Syfovre and Empaveli to Biogen’s portfolio of medicines.
Biogen Inc. forecast 2026 profit above Wall Street’s expectations, signaling that steep cost-cutting measures are cushioning the impact of shrinking sales from its multiple sclerosis franchise.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results